Impact of vancomycin minimum inhibitory concentration on mortality among critically ill patients with methicillin-resistant staphylococcus aureus bacteremia

Infection Control and Hospital Epidemiology

Volumn 33, Issue 12, 2012, Pages 1246-1249

  Woods, Christian J ^a,b   Chowdhury, Anindita ^a   Patel, Vinay M ^a   Shorr, Andrew F ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL ENDOCARDITIS; CRITICALLY ILL PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PROBABILITY; RETROSPECTIVE STUDY; SHOCK;

AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; CONFIDENCE INTERVALS; CRITICAL ILLNESS; ENDOCARDITIS; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SHOCK; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84869164960     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/668433     Document Type: Article

References (10)

1. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46:S360-S367.
2. Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46:2950-2954.
3. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vanco-mycin. Antimicrob Agents Chemother 2008;52:3315-3320.
4. Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Anti-microb Agents Chemother 2007;51:2582-2586.
5. Hawkins C, Huang J, Jin N, et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007;167:1861-1867.
6. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphy-lococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47:1640-1644.
7. Price J, Atkinson S, Llewelyn M, et al. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacter-emia and the minimum inhibitory concentration of vancomy-cin. Clin Infect Dis 2009;48:997-998.
8. Sader HS, Fey PD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009;53:4127-4132.
9. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of meth-icillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
10. van Hall SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphy-lococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis (in press).